$465.67
Value $251B
AMGN and CHE stock compared: price, dividend, valuation and results, from SEC filings.
$465.67
Value $251B
$548.20
Value $7.1B
Amgen (AMGN) has a market value of $251B and Chemed (CHE) $7.1B. Over the last year, with dividends, AMGN moved +42.3% and CHE +23.1%. The P/E is 26.7 for AMGN and 25.3 for CHE. Dividend yield: AMGN 2.13%, CHE 0.46%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
AMGN$251B
CHE$7.1B
AMGN is 35 times CHE
Revenue, 12 months
AMGN$38.9B
CHE$2.7B
AMGN is 15 times CHE
Net income, 12 months
AMGN$9.4B
CHE$282M
AMGN is 33 times CHE
Operating margin
AMGN32.4%
CHE13.9%
18.5 points apart
ROIC
AMGN16.2%
CHE26.5%
10.3 points apart
P/E
AMGN26.7
CHE25.3
AMGN is 1.1 times CHE
Dividend yield
AMGN2.1%
CHE0.5%
1.6 points apart
5-year return
AMGN+157.4%
CHE+11.2%
146.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
AMGN+157.4%
CHE+11.2%
| Period | AMGNWith dividends | CHEWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +42.3%Price +38.5% | +23.1%Price +22.5% |
| 3 years since November 13, 2023 | +91.0%+24.1% a yearPrice +74.6% | -4.9%-1.6% a yearPrice -6.0% |
| 5 years since November 12, 2021 | +157.4%+20.8% a yearPrice +120.3% | +11.2%+2.1% a yearPrice +9.2% |
| 10 years since November 16, 2016 | +323.1%+15.5% a yearPrice +216.3% | +289.7%+14.6% a yearPrice +276.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
AMGNAmgenCHEChemed
| Price | $465.67 | $548.20 |
|---|---|---|
| Market value | $251B | $7.1B |
| Enterprise value (EV) | $292B | $7.3B |
| P/E | 26.7 | 25.3 |
| P/E, 5-year median | 23.0 | 30.9 |
| P/B | 17.5 | 8.3 |
| EV/EBIT | 23.1 | 19.7 |
| Free cash flow yield | 3.8% | 4.1% |
| Revenue, 12 months | $38.9B | $2.7B |
|---|---|---|
| Net income, 12 months | $9.4B | $282M |
| Free cash flow, 12 months | $9.6B | $296M |
| Earnings per share, 12 months | $17.25 | $20.87 |
| Revenue growth, year on year | 10.0% | 4.1% |
| Revenue growth a year, past | +7.6%over 5 years | +4.0%over 5 years |
| EPS growth a year, past | +2.9%over 5 years | -1.2%over 5 years |
| Gross margin | 70.9% | 33.5% |
|---|---|---|
| Operating margin | 32.4% | 13.9% |
| Net margin | 24.1% | 10.6% |
| ROIC | 16.2% | 26.5% |
| ROE | 87.8% | 30.7% |
| Cash | $13.2B | $48M |
|---|---|---|
| Total debt | $54.0B | $392M |
| Net debt / EBITDA | 2.3 | 0.4 |
| Interest cover | 4.8× | 75.4× |
| Dividend yield | 2.1% | 0.5% |
|---|---|---|
| Dividend per share, 12 months | $9.94 | $2.50 |
| Dividend growth a year, past | +8.1%over 5 years | +10.8%over 5 years |
| Buyback yield | – | 6.1% |
| Shareholder yield | 2.1% | 6.5% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Amgen ($251B) is about 35.2 times Chemed ($7.1B), at today's prices.
Since November 16, 2016, AMGN's price moved +216.3% and CHE's +276.0%. With dividends: AMGN +323.1% (+15.5% a year), CHE +289.7% (+14.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.13% for Amgen and 0.46% for Chemed. Over the last twelve months they paid $9.94 and $2.50 per share.
At today's price, the P/E is 26.7 for AMGN and 25.3 for CHE. The median of the last five years was 23.0 and 30.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 24.1% for Amgen and 10.6% for Chemed, and the operating margin 32.4% and 13.9%. Revenue was $38.9B and $2.7B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.